Malin Wickström Näsman

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: CANCER LETTERS. 2024;605:217261
The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma
Pepich A; Tummler C; Abu Ajamieh S; Treis D; Boje AS; Vellema Q; Tsea I; Akerlund E; Seashore-Ludlow B; Fard SS; Kogner P; Johnsen JI; Wickstrom M
Article: BLOOD. 2024;143(19):1953-1964
SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma
Morsy MHA; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gomez M; Amador V; Johansson HJ; Lehtio J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickstrom M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Article: JCI INSIGHT. 2024;9(6):e173337
Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic
Mei S; Alchahin AM; Embaie BT; Gavriliuc IM; Verhoeven BM; Zhao T; Li X; Jeffries NE; Pepich A; Sarkar H; Olsen TK; Wickstrom M; Stenman J; Reina-Bedoya O; Kharchenko PV; Saylor PJ; Johnsen JI; Sykes DB; Kogner P; Baryawno N
Article: JOURNAL OF THE ENDOCRINE SOCIETY. 2024;8(3):bvae009
Humanin Treatment Protects Against Venetoclax-Induced Bone Growth Retardation in Ex Vivo Cultured Rat Bones.
Velentza L; Wickström M; Kogner P; Ohlsson C; Zaman F; Sävendahl L
Article: SCIENTIFIC REPORTS. 2023;13(1):8054
Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth
Velentza L; Wickstrom M; Kogner P; Ohlsson C; Zaman F; Savendahl L
Journal article: FRONTIERS IN PHARMACOLOGY. 2023;14:1183720
The multiple functions of miR-574-5p in the neuroblastoma tumor microenvironment.
Proestler E; Donzelli J; Nevermann S; Breitwieser K; Koch LF; Best T; Fauth M; Wickström M; Harter PN; Kogner P; Lavieu G; Larsson K; Saul MJ
Article: FRONTIERS IN PHARMACOLOGY. 2023;14:1183720
The multiple functions of miR-574-5p in the neuroblastoma tumor microenvironment
Proestler E; Donzelli J; Nevermann S; Breitwieser K; Koch LF; Best T; Fauth M; Wickstrom M; Harter PN; Kogner P; Lavieu G; Larsson K; Saul MJ
Article: LIFE SCIENCES. 2022;295:120394
Omega-3 fatty acids decrease CRYAB, production of oncogenic prostaglandin E₂ and suppress tumor growth in medulloblastoma
Ljungblad L; Bergqvist F; Tummler C; Madawala S; Olsen TK; Andonova T; Jakobsson P-J; Johnsen JI; Pickova J; Strandvik B; Kogner P; Gleissman H; Wickstrom M
Article: CANCER RESEARCH COMMUNICATIONS. 2022;2(3):182-201
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner
Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickstrom M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson L-G
Article: NATURE COMMUNICATIONS. 2022;13(1):1537
GIT1 protects against breast cancer growth through negative regulation of Notch
Zhang S; Miyakawa A; Wickstrom M; Dyberg C; Louhivuori L; Varas-Godoy M; Kemppainen K; Kanatani S; Kaczynska D; Ellstrom ID; Elfman L; Kronqvist P; Repo H; Mikoshiba K; Sahlgren C; Johnsen JI; Uhlen P
Article: FRONTIERS IN ONCOLOGY. 2022;12:906194
The cyclin dependent kinase inhibitor p21^Cip1/Waf1 is a therapeutic target in high-risk neuroblastoma
Sorteberg AL; Halipi V; Wickstroem M; Shirazi Fard S
Article: CANCERS. 2021;13(23):6042
PPM1D Is a Therapeutic Target in Childhood Neural Tumors
Milosevic J; Treis D; Fransson S; Gallo-Oller G; Sveinbjoernsson B; Eissler N; Tanino K; Sakaguchi K; Martinsson T; Wickstroem M; Kogner P; Johnsen JI
Article: CELL DEATH & DISEASE. 2021;12(10):914
Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound
Giovannucci TA; Salomons FA; Haraldsson M; Elfman LHM; Wickstroem M; Young P; Lundbaeck T; Eirich J; Altun M; Jafari R; Gustavsson A-L; Johnsen JI; Dantuma NP
Article: PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS. 2021;169:102285
Body surface area-based omega-3 fatty acids supplementation strongly correlates to blood concentrations in children.
Ljungblad L; Gleissman H; Hedberg G; Wickstrom M; Eissler N; Pickova J; Johnsen JI; Tedroff K; Strandvik B; Kogner P
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2021;58(2):211-225
Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines
Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickstrom M; Kostopoulou ON; Dalianis T
Article: ANTICANCER RESEARCH. 2020;40(1):53-66
Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines
Holzhauser S; Lukoseviciute M; Andonova T; Ursu RG; Dalianis T; Wickstrom M; Kostopoulou ON
Article: CANCERS. 2019;12(1):E73-73
Inhibition of Rho-Associated Kinase Suppresses Medulloblastoma Growth
Dyberg C; Andonova T; Olsen TK; Brodin B; Kool M; Kogner P; Johnsen JI; Wickstrom M
Article: ONCOLOGY LETTERS. 2019;18(6):6249-6260
In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines
Holzhauser S; Kostopoulou ON; Ohmayer A; Lange BKA; Ramqvist T; Andonova T; Bersani C; Wickstrom M; Dalianis T
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2019;55(6):1372-1384
Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines
Kostopoulou ON; Holzhauser S; Lange BKA; Ohmayer A; Andonova T; Bersani C; Wickstrom M; Dalianis T
Article: CANCERS. 2019;11(2):E202-202
SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells In Vitro
Tummler C; Dumitriu G; Wickstrom M; Coopman P; Valkov A; Kogner P; Johnsen JI; Moens U; Sveinbjornsson B
Article: PHARMACOLOGICAL RESEARCH. 2018;131:164-176
Molecular mechanisms and therapeutic targets in neuroblastoma
Johnsen JI; Dyberg C; Fransson S; Wickstrom M
Article: ONCOTARGET. 2017;8(56):95135-95151
Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo
Tummler C; Snapkov I; Wickstrom M; Moens U; Ljungblad L; Elfman LHM; Winberg J-O; Kogner P; Johnsen JI; Sveinbjornsson B
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2017;114(32):E6603-E6612
Rho-associated kinase is a therapeutic target in neuroblastoma
Dyberg C; Fransson S; Andonova T; Sveinbjornsson B; Lannerholm-Palm J; Olsen TK; Forsberg D; Herlenius E; Martinsson T; Brodin B; Kogner P; Johnsen JI; Wickstrom M
Article: ONCOTARGET. 2017;8(21):34111-34127
Lithium protects hippocampal progenitors, cognitive performance and hypothalamus-pituitary function after irradiation to the juvenile rat brain
Zhou K; Xie C; Wickstrom M; Dolga AM; Zhang Y; Li T; Xu Y; Culmsee C; Kogner P; Zhu C; Blomgren K
Article: SCIENTIFIC REPORTS. 2017;7:46366
Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation
Sanden E; Dyberg C; Krona C; Gallo-Oller G; Olsen TK; Perez JE; Wickstrom M; Estekizadeh A; Kool M; Visse E; Ekstrom TJ; Siesjo P; Johnsen JI; Darabi A
Article: BMC CANCER. 2016;16:263
In vitro and in vivo activity of melflufen (J1)in lymphoma
Delforoush M; Strese S; Wickstrom M; Larsson R; Enblad G; Gullbo J
Article: BMC CANCER. 2016;16:259
Planar cell polarity gene expression correlates with tumor cell viability and prognostic outcome in neuroblastoma
Dyberg C; Papachristou P; Haug BH; Lagercrantz H; Kogner P; Ringstedt T; Wickstrom M; Johnsen JI
Article: MOLECULAR & CELLULAR ONCOLOGY. 2016;3(2):e1131356
Wingless/β-catenin signaling as a modulator of chemoresistance in cancer
Johnsen JI; Wickstrom M; Baryawno N
Article: NATURE COMMUNICATIONS. 2015;6:8904
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance
Wickstrom M; Dyberg C; Milosevic J; Einvik C; Calero R; Sveinbjornsson B; Sanden E; Darabi A; Siesjo P; Kool M; Kogner P; Baryawno N; Johnsen JI
Article: BMC CANCER. 2014;14:600
The impact of S6K1 kinase on neuroblastoma cell proliferation is independent of GLI1 signaling
Diao Y; Rahman MF-U; Villegas VE; Wickstrom M; Johnsen JI; Zaphiropoulos PG
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2014;106(3):djt459
Protective Role of Humanin on Bortezomib-Induced Bone Growth Impairment in Anticancer Treatment
Eriksson E; Wickstrom M; Perup LS; Johnsen JI; Eksborg S; Kogner P; Savendahl L
Article: BIOCHEMICAL PHARMACOLOGY. 2013;86(7):888-895
The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo
Strese S; Wickstrom M; Fuchs PF; Fryknas M; Gerwins P; Dale T; Larsson R; Gullbo J
Article: BMC CANCER. 2013;13:374
Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
Fryknas M; Gullbo J; Wang X; Rickardson L; Jarvius M; Wickstrom M; Hassan S; Andersson C; Gustafsson M; Westman G; Nygren P; Linder S; Larsson R
Article: MOLECULAR CANCER THERAPEUTICS. 2013;12(8):1526-1536
Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro
Wu X; Sooman L; Wickstrom M; Fryknas M; Dyrager C; Lennartsson J; Gullbo J
Article: INTERNATIONAL JOURNAL OF CANCER. 2013;132(7):1516-1524
Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo
Wickstrom M; Dyberg C; Shimokawa T; Milosevic J; Baryawno N; Fuskevag OM; Larsson R; Kogner P; Zaphiropoulos PG; Johnsen JI
Article: BLOOD CANCER JOURNAL. 2012;2(8):e81
The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia
Eriksson A; Hermanson M; Wickstrom M; Lindhagen E; Ekholm C; Jensen AJ; Lothgren A; Lehmann F; Larsson R; Parrow V; Hoglund M
Article: CELL DEATH & DISEASE. 2012;3(4):e298
Wig-1, a novel regulator of N-Myc mRNA and N-Myc-driven tumor growth
Vilborg A; Bersani C; Wickstrom M; Segerstrom L; Kogner P; Wiman KG
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2012;69(3):697-707
In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues
Haglund C; Aleskog A; Nygren P; Gullbo J; Hoglund M; Wickstrom M; Larsson R; Lindhagen E
Article: INTERNATIONAL JOURNAL OF CANCER. 2011;129(12):2958-2965
Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo
Segerstrom L; Baryawno N; Sveinbjornsson B; Wickstrom M; Elfman L; Kogner P; Johnsen JI
Article: BIOCHEMICAL PHARMACOLOGY. 2011;82(2):139-147
Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment
Gullbo J; Fryknas M; Rickardson L; Darcy P; Hagg M; Wickstrom M; Hassan S; Westman G; Brnjic S; Nygren P; Linder S; Larsson R
Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2011;19(8):2659-2665
Inhibitors and promoters of tubulin polymerization: Synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents
Dyrager C; Wickstrom M; Friden-Saxin M; Friberg A; Dahlen K; Wallen EAA; Gullbo J; Grotli M; Luthman K
Article: THROMBOSIS RESEARCH. 2011;127(2):141-148
Tissue Factor/FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1)
Aberg M; Johnell M; Wickstrom M; Siegbahn A
Article: EUROPEAN JOURNAL OF ORGANIC CHEMISTRY. 2010;2010(32):6171-6178
Synthesis and Characterization of a Multi Ring-Fused 2-Pyridone-Based Fluorescent Scaffold
Sellstedt M; Nyberg A; Rosenbaum E; Engstrom P; Wickstrom M; Gullbo J; Bergstrom S; Johansson LB-A; Almqvist F
Article: BIOCHEMICAL PHARMACOLOGY. 2010;79(9):1281-1290
The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
Wickstrom M; Viktorsson K; Lundholm L; Aesoy R; Nygren H; Sooman L; Fryknas M; Vogel LK; Lewensohn R; Larsson R; Gullbo J
Article: ANTICANCER RESEARCH. 2010;30(1):149-156
The Cytotoxic Agents NSC-95397, Brefeldin A, Bortezomib and Sanguinarine Induce Apoptosis in Neuroendocrine Tumors In Vitro
Larsson DE; Wickstrom M; Hassan S; Oberg K; Granberg D
Article: MOLECULAR & CELLULAR PROTEOMICS. 2010;9(1):178-183
High Content Screening for Inhibitors of Protein Interactions and Post-translational Modifications in Primary Cells by Proximity Ligation
Leuchowius K-J; Jarvius M; Wickstrom M; Rickardson L; Landegren U; Larsson R; Soderberg O; Fryknas M; Jarvius J
Article: JOURNAL OF NATURAL PRODUCTS. 2009;72(11):1969-1974
Cytotoxic Effects of Cardiac Glycosides in Colon Cancer Cells, Alone and in Combination with Standard Chemotherapeutic Drugs
Felth J; Rickardson L; Rosen J; Wickstrom M; Fryknas M; Lindskog M; Bohlin L; Gullbo J
Article: INTERNATIONAL JOURNAL OF CANCER. 2009;124(5):1227-1234
Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo
Paimberg E; Johnsen JI; Paulsson J; Gleissman H; Wickstrom M; Edgren M; Ostman A; Kogner P; Lindskog M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2008;81(5):344-353
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia
Lindhagen E; Eriksson A; Wickstrom M; Danielsson K; Grundmark B; Henriksson R; Nygren P; Aleskog A; Larsson R; Hoglund M
Article: THROMBOSIS AND HAEMOSTASIS. 2008;100(4):655-662
Simvastatin reduces the production of prothrombotic prostasomes in human prostate cancer cells
Aberg M; Johnell M; Wickstrom M; Widunder A; Siegbahn A
Article: INVESTIGATIONAL NEW DRUGS. 2008;26(3):195-204
The novel alkylating prodrug J1:: diagnosis directed activity profile ex vivo and combination analyses in vitro
Wickstroem M; Haglund C; Lindman H; Nygren P; Larsson R; Gullbo J
Article: THROMBOSIS RESEARCH. 2008;122(2):191-202
Simvastatin induces apoptosis in human breast cancer cells in a NFκB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa
Aberg M; Wickstrom M; Siegbahn A
Article: MOLECULAR CANCER THERAPEUTICS. 2007;6(9):2409-2417
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
Wickstrom M; Johnsen JI; Ponthan F; Segerstrom L; Sveinbjornsson B; Lindskog M; Lovborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
Article: JOURNAL OF BIOMOLECULAR SCREENING. 2007;12(2):203-210
Image-based screening for the identification of novel proteasome inhibitors
Rickardson L; Wickstrom M; Larsson R; Lovborg H
Article: CLINICAL CANCER RESEARCH. 2007;13(3):1036-1044
Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo
Ponthan F; Wickstroem M; Gleissman H; Fuskevag OM; Segerstroem L; Sveinbjoernsson B; Redfern CPF; Eksborg S; Kogner P; Johnsen JI
Article: BIOCHEMICAL PHARMACOLOGY. 2007;73(1):25-33
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients
Wickstrom M; Danielsson K; Rickardson L; Gullbo J; Nygren P; Isaksson A; Larsson R; Lovborg H
Article: JOURNAL OF BIOMOLECULAR SCREENING. 2006;11(5):457-468
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model
Fryknas M; Rickardson L; Wickstrom M; Dhar S; Lovborg H; Gullbo J; Nygren P; Gustafsson MG; Isaksson A; Larsson R
Article: JOURNAL OF DRUG TARGETING. 2003;11(6):355-363
Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1
Gullbo J; Wickström M; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
Visa fler

Alla övriga publikationer

Review: FRONTIERS IN MOLECULAR NEUROSCIENCE. 2019;12:9
Neuroblastoma - A Neural Crest Derived Embryonal Malignancy
Johnsen JI; Dyberg C; Wickstrom M
Review: ONCOTARGET. 2017;8(39):66641-66655
Melflufen - a peptidase-potentiated alkylating agent in clinical trials
Wickstrom M; Nygren P; Larsson R; Harmenberg J; Lindberg J; Sjoberg P; Jerling M; Lehmann F; Richardson P; Anderson K; Chauhan D; Gullbo J
Review: CANCER SCIENCE. 2011;102(3):501-508
Aminopeptidase N (CD13) as a target for cancer chemotherapy
Wickstrom M; Larsson R; Nygren P; Gullbo J
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2010;8(7):145
Validation of a cell panel for preclinical evaluation of antitumor efficacy and toxicity of anticancer agents
Haglund C; Aleskog A; Nygren P; Gullbo J; Hoglund M; Wickstrom M; Larsson R; Lindhagen E
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2010;8(7):69
The alkylating prodrug J1 inhibits ovarian cancer cell growth, activates proapoptotic signalling and potentiates gemcitabine responsiveness in vitro and in vivo in mice
Viktorsson K; Gullbo J; Juntti T; Wickstrom M; Larsson R; Lewensohn R; Spira J

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI